Vivid Microscopy’s technology detects stages of microvascular heart disease using an animal-based model, as demonstrated in a University of Louisville study

Vivid Microscopy’s high content screening probes are now widely available through biotech suppliers Kerafast Inc.

WAUWATOSA, Wis., October 26, 2022 /PRNewswire/ — Living microscopyan emerging biotech company in The United Statestoday announced the successful use of its high-content screening probe SEMKUR-IM in a study conducted by University of Louisville to coronary microvascular disease (CMD) in postmenopausal women.

Microvascular dysfunction, a disease affecting over 3 million women annually, often presents with chest pain and shortness of breath, which can lead to heart failure. The current detection method is an angiogram or a special form of ultrasound. Early detection of the microvascular dysregulation signal is crucial – if it goes undetected, it can lead to heart failure or a massive heart attack.

In experiments of University of Louisville Published in Antioxidant and redox signalingThe scientists examined four different states of cells and used different indicators to assess each state. Vivid’s probe was unique in that it could detect (with minimal standard deviation) all stages of TMD affecting the heart’s blood supply. Using fluorescence technology, the SEMKUR-IM tool was able to differentiate the severity of the disease from the initial stages to the most extreme, and to assess the effectiveness of drugs aimed at treating the disease.

‚ÄúVivid Microscopy’s product was the only technology we could find that could detect glutathione in living cells. SEMKUR-IM was the only product that could be made in our physiological saline solution and then infused. Most other fluorescent products required cell or tissue fixation first, which would not allow us to study in real time how glutathione levels change during response to stimuli such as intraluminal fluid flow or drug agonists,” explained Dr. Eva Tracy of University of Louisvilleworks under the direction of Dr. Amanda LeBlanc.

That University of Louisville Study showed how Vivid’s probe can be used to determine the effectiveness of new cardiovascular treatments. Corresponding Jayson KurfisCEO of Vivid Microscopy, “These methods offer the opportunity to significantly improve a patient’s quality of life while reducing mortality, making SEMKUR-IM an invaluable tool for the development of drugs and interventions to treat heart disease.”

Scientists, researchers and the medical community can now purchase these pre-clinical assessment tools from kerafast.coman online platform that gives researchers access to unique laboratory-made bioresearch materials.


At Vivid Microscopy, our mission is to improve the speed and accuracy of preclinical assessment tools that provide researchers and scientists with quantitative results. Using fluorescence technology to detect biomarkers associated with cell damage, Vivid Microscopy has developed SEMKUR-IM, a quantitative test to assess cell damage. We strive to provide scientists and researchers with predictive technologies that can be used to facilitate disease diagnosis and drug development. Living microscopy has its registered office in Wauwatosa, WI and manufactures its products in the United States of America.

SOURCE Living Microscopy


Leave a Reply

Your email address will not be published. Required fields are marked *